Table 2 Ezrin overexpression and clinicopathological features of cervical cancers
From: High expression of ezrin predicts poor prognosis in uterine cervical cancer
Clinical features | Cases (n) | Strongly positive cases n. (%) | P-value |
|---|---|---|---|
Histological types | 226 | Â | Â |
  Keratinizing | 125 | 96 (76.8%) | NS |
  Non-keratinizing | 101 | 71 (70.3%) |  |
Differentiation | 235 | Â | Â |
  Poorly diff. | 35 | 33 (94.3%)* | <0.05a |
  Moderately diff. | 106 | 89 (84.0%)* |  |
  Well diff. | 94 | 53 (56.4%) |  |
Staging | 235 | Â | Â |
 Early (I-IIA) | 108 | 53 (49.1%) | <0.05b |
  IA | 16 | 5 (31.3%) |  |
  IB | 41 | 22 (53.7%) |  |
  IIA | 51 | 26 (51.0%) |  |
 Late (IIB-IV) | 127 | 122 (96.1%)** |  |
  IIB | 11 | 9 (81.8%) |  |
  IIIA | 12 | 11 (91.7%) |  |
  IIIB | 46 | 44 (95.7%) |  |
  IVA | 41 | 41 (100%) |  |
  IVB | 17 | 17 (100%) |  |
LN Metastasis | 235 | Â | Â |
  Positive |   104 | 104 (100%)* | <0.05 |
  Negative |   131 | 71 (54.2%) |  |